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Abstract 
Sentinel lymph node biopsy (SLNB) is commonly performed in cancers that metastasise via the lymphatic 
system. It involves excision and histology of sentinel lymph nodes (SLNs) and presents two main challenges: (i) 
sensitive whole-body localisation of SLNs, and (ii) lack of pre-operative knowledge of their metastatic status, 
resulting in a high number (>70%) of healthy SLN excisions. To improve SLNB, whole-body imaging could 
improve detection and potentially prevent unnecessary surgery by identifying healthy and metastatic SLNs. In 
this context, radiolabelled SPIOs and PET-MRI could find applications to locate SLNs with high sensitivity at the 
whole-body level (using PET) and guide high-resolution MRI to evaluate their metastatic status. Here we 
evaluate this approach by synthesising a GMP-compatible 68Ga-SPIO (68Ga-Sienna+) followed by PET-MR 
imaging and histology studies in a metastatic breast cancer mouse model. 
Methods. A clinically approved SPIO for SLN localisation (Sienna+) was radiolabelled with 68Ga without a 
chelator. Radiochemical stability was tested in human serum. In vitro cell uptake was compared between 
3E.Δ.NT breast cancer cells, expressing the hNIS reporter gene, and macrophage cell lines (J774A.1; 
RAW264.7.GFP). NSG-mice were inoculated with 3E.Δ.NT cells. Left axillary SLN metastasis was monitored 
by hNIS/SPECT-CT and compared to the healthy right axillary SLN. 68Ga-Sienna+ was injected into front paws 
and followed by PET-MRI. Imaging results were confirmed by histology. 
Results. 68Ga-Sienna+ was produced in high radiochemical purity (>93%) without the need for purification and 
was stable in vitro. In vitro uptake of 68Ga-Sienna+ in macrophage cells (J774A.1) was significantly higher (12 ± 
1%) than in cancer cells (2.0 ± 0.1%; P < 0.001). SPECT-CT confirmed metastasis in the left axillary SLNs of 
tumour mice. In PET, significantly higher 68Ga-Sienna+ uptake was measured in healthy axillary SLNs (2.2 ± 0.9 
%ID/mL), than in metastatic SLNs (1.1 ± 0.2 %ID/mL; P = 0.006). In MRI, 68Ga-Sienna+ uptake in healthy SLNs 
was observed by decreased MR signal in T2/T2*-weighted sequences, whereas fully metastatic SLNs appeared 
unchanged. 
Conclusion. 68Ga-Sienna+ in combination with PET-MRI can locate and distinguish healthy from metastatic 
SLNs and could be a useful preoperative imaging tool to guide SLN biopsy and prevent unnecessary excisions. 
Key words: 68Ga, PET-MRI, sentinel lymph node biopsy, SPIO 
Introduction 
Several cancers such as melanoma, breast and 
prostate cancer are known to spread through the 
lymphatic system [1]. Sentinel lymph nodes (SLN) are 
described as the first nodes to receive lymphatic 
drainage from a tumour and sentinel lymph node 
biopsy (SLNB) involves the identification of SLNs for 
removal and histopathological analysis to evaluate 








information, clinicians decide whether or not further 
surgery is indicated. Surgical removal of metastatic 
SLNs and SLNB can improve disease-free interval and 
increase survival rate [2,3]. However, >70% of excised 
SLNs in breast cancer or melanoma have been found 
to be negative/healthy SLNs, exposing these patients 
to unnecessary surgery and post-operative risks such 
as lymphoedema, seroma formation and nerve or 
vessel damage [4]. Thus, a non-invasive preoperative 
imaging method of locating and discriminating 
between metastatic and healthy SLNs would be an 
important tool to avoid unnecessary biopsies and 
improve guidance for SLNB. 
 Several clinical imaging methods are available 
for the detection of SLNs. Ultrasound and computed 
tomography (CT) have been used to find enlarged 
SLNs, but size is not a suitable indicator for metastasis 
[5]. 99mTc-nanocolloid mixed with a blue/fluorescent 
dye can be used for SLN imaging by 
lymphoscintigraphy or single-photon emission 
computed tomography (SPECT) [6]. However, these 
imaging techniques only locate SLNs, and do not 
detect the presence of metastasis. [18F]FDG positron 
emission tomography (PET) is useful to identify 
macrometastases but not micrometastases (size 
between 0.2 – 2 mm) and it may be difficult to locate 
metastases in LNs in close proximity to areas of high 
[18F]FDG uptake [7]. Dynamic [18F]FDG 
PET-lymphography is a recent promising technique 
where the radiotracer is injected subcutaneously, and 
has been shown to be efficient at locating and 
characterizing SLNs but lacks sensitivity in 
differentiating acute inflammatory lymphadenopathy 
from metastatic LNs [8]. Photoacoustic imaging has 
also shown promise for detecting LN micrometastases 
in melanoma [9,10]. 
MRI has excellent spatial resolution and, in 
combination with superparamagnetic iron oxide 
nanoparticles (SPIOs), is capable of detecting 
micrometastases in the clinical setting at very low 
SPIO concentrations [11,12]. SPIOs are taken up by 
macrophages where they accumulate creating 
negative contrast (low signal intensity in T2/T2* 
weighted MRI) in the healthy tissue of SLNs, but not 
in metastatic LN tissue that lacks high concentrations 
of macrophages [4]. This property has resulted in the 
identification of contrast patterns of SLN uptake for 
metastatic and non-metastatic nodes [13]. The low 
sensitivity of MRI, however, makes whole-body 
identification of SPIO biodistribution and SLN 
localisation challenging, which is an important 
consideration in cancers with distant SLNs and/or 
variable location of the primary tumour, such as 
melanoma [14].  
 One approach to overcome this limitation of 
SPIO-MRI is to combine the full-body imaging 
capabilities and sensitivity of PET with the ability of 
SPIO-MRI to identify SLN metastases using 
radiolabelled SPIOs. This approach would allow the 
use of PET for both sensitive whole-body SLN 
localisation and also guiding high resolution MRI for 
evaluating intra-LN SPIO distribution. Several 
groups, including ours, have previously 
demonstrated the concept of SLN localisation with 
radiolabelled SPIOs using nuclear-MR imaging; 
however, to the best of our knowledge, none have 
demonstrated localisation and characterisation in a 
metastatic animal cancer model [15-28]. The aim of 
this work was to develop a clinically translatable 
68Ga-labelled PET-MR SLN imaging agent based on a 
CE-approved SPIO for SLN localisation (Sienna+). To 
evaluate its potential in a relevant metastatic mouse 
cancer model, we chose a reporter gene (human 
sodium iodide symporter - hNIS) expressing breast 
cancer mouse model that develops spontaneous 
axillary lymph node metastases and allows the use of 
SPECT imaging with 99mTcO4- (hNIS substrate) to 
confirm the health status of SLNs prior to 
68Ga-Sienna+ PET-MRI (Scheme 1).  
Materials and Methods 
Radiolabelling of Sienna+ with 68Ga 
Sienna+ SPIO nanoparticles with 
carboxydextran coating (26–30 mg Fe/mL, Z-average 
diameter 59 ± 0.7 nm; pH = 5.0–7.0; sterile) were 
purchased from Endomag (Cambridge, UK). 68Ga (t1/2 
= 68 min, β+ = 89%) was eluted from a 
68Ge/68Ga-generator (Eckert & Ziegler, Germany) 
with 5 mL of 0.1 M HCl for high performance 
capillary electrophoresis (HPCE) (Fluka, USA). The 
pH of the gallium elution (400 µL) was adjusted to 5 
with 4 M ammonium acetate solution (40 µL, 160 
µmol, Sigma-Aldrich, UK), Sienna+ (67 µL, 2 mg Fe) 
was then added and the mixture reacted in a sealed 
1.5 mL plastic microcentrifuge tube at 100 °C for 10 
min. The reaction solution was filtered (sterile 
hydrophilic Millex-LG 13 mm 0.2 µm PTFE, Merck, 
Germany). The pH of the final product was ~6. 
Radiolabelling using GMP protocol: A CE-approved 
sterile vial of Sienna+ (2 mL, 60 mg Fe) was injected 
with 100 µL of the pH-adjusted 68Ga elution (pH 5) 
using sterile techniques with a 1 mL syringe and filter 
(same as above). The vial was incubated at 100 °C for 
10 min. After cooling, the radiochemical purity of 
68Ga-Sienna+ was measured using TLC (F-254 silica 
gel 60 plates, Merck) with citrate buffer (pH 5) as an 
eluent (0.1 M tri-sodium citrate dihydrate 
(Sigma-Aldrich) and 0.1 M citric acid monohydrate 




(Fisher Scientific, UK)) and analysed by 
autoradiography. Exposed phosphor screens 
(PerkinElmer, USA) were scanned with a Cyclone 
Plus system (PerkinElmer). The percentage of 
68Ga-Sienna+ and free 68Ga were calculated by region 
of interest (ROI) analysis using OptiQuant 5.0 
software (PerkinElmer). Nanoparticle hydrodynamic 
size was measured by dynamic light scattering (DLS) 
and the effective electric charge of the surface by zeta 
potential measurements in a Zetasizer Nano ZS 
instrument (Malvern Instruments Ltd, UK) in 
deionised water (size) or 10% PBS (zeta potential). 
In vitro serum stability 
68Ga-Sienna+ (100 µL, 10 MBq, 0.3 mg Fe) was 
mixed with human serum (900 µL, Sigma-Aldrich) 
and the mixture incubated at 37 °C for 4 h. Samples 
(200 µL) were collected every hour and analysed by 
size-exclusion chromatography with a Superose 6 
Increase 10/300 GL column (GE Healthcare, UK) 
connected to an Äkta system (GE Healthcare) using a 
0.5 mL/min flow of PBS as eluent. Samples of 1 mL 
were collected and measured in a gamma counter 
(LKB Wallac, Finland). 68Ga-Sienna+ eluted at 8–15 
mL and serum-bound/free 68Ga at 20–25 mL. Serum 
stability was expressed as percentage of 68Ga-Sienna+ 
in serum (as calculated from size-exclusion 
chromatography) over time.  
Cell culture and in vitro uptake studies 
Rat breast adenocarcinoma cells MTLn3E 
Δ34-CXCR4-GFP hNISTagRFP (3E.Δ.NT) were 
generated and characterised as previously described 
[29]. Mouse monocyte macrophages J774A.1 were a 
gift from Dr. Varsha Kanabar at the Institute of 
Pharmaceutical Sciences in King’s College London. 
Generation and characterisation of mouse leukaemic 
monocyte macrophage RAW264.7.GFP cells are 
described in the supplemental information. All cell 
lines were maintained in an atmosphere of 5% 
CO2/95% air. All cell culture reagents were obtained 
from Sigma-Aldrich. 3E.Δ.NT cells were cultured in 
MEM eagle with alpha modification supplemented 
with 5% FBS, 100 IU penicillin-streptomycin, 0.5 
mg/mL G 418 disulfate salt and 0.5 µg/mL 
puromycin. Macrophage cell lines were cultured in 
DMEM high glucose medium supplemented with 
10% FBS and 1 mM sodium pyruvate. All cell media 
were supplemented with 2 mM L-glutamine. 
For cell uptake studies of 68Ga-Sienna+, each cell 
line was cultured on 6-well plates 24 h before the 
experiment using 1 million cells/well. The medium 
was then removed and 1 mL of 68Ga-Sienna+ solution 
in complete medium was added (600 kBq/mL, 5.3 µg 
iron/mL). Cells were incubated for 1, 2 or 3 h. The 
supernatant was collected and cells washed twice 
with PBS. 3E.Δ.NT cells were collected by 
trypsination. Macrophages were collected by 
scraping. The radioactivity of the samples (cell pellet, 
supernatant and washings) was measured in a 
gamma counter to allow us to calculate cell uptake, 
expressed as a percentage of total radioactivity per 
million cells. 
Animal experiments 
Animal experiments were approved by the 
King's College London Animal Welfare and Ethical 
Review Body (AWERB) and were in agreement with 
UK Home Office regulations. Female 5–6 weeks old 








Il2rgtm1Wjl/SsJ, n = 6) and B6CBAF1 mice were obtained 
from Charles River (UK). Mice were housed within 
filter-top cages at least 5 days before starting the 
experiments and given food and water ad libitum. For 
tumour inoculation, 3E.Δ.NT cells (1 × 106 cells in 50 
µL of PBS) were injected subcutaneously into the left 
mammary fat pad between the fourth and fifth nipple 
in the NSG mice. Once tumours were palpable, their 
volume was monitored using calipers. During tumour 
inoculation and imaging procedures, mice were 
anaesthetised with isoflurane (Vet Tech Solutions 
Ltd., UK), 3% in oxygen for induction and 1.5–2% for 
maintenance. 
SPECT-CT and PET-CT imaging 
On day 19 or 20 after inoculation, NSG mice 
were scanned with SPECT-CT using 
99mTc-pertechnetate (99mTcO4−) to confirm metastasis 
of left axillary SLNs. 99mTcO4− was eluted from a 
Drytec generator (GE Healthcare) using saline. 
99mTcO4− (100 µL, 31 ± 3 MBq) was injected 
intravenously into the tail vein. After 40 min, a 30 min 
scan was acquired on a NanoSPECT-CT Silver 
Upgrade (Mediso, Hungary) with 1 mm collimators, 
45 s/frame. CT was obtained with 55 kVp tube 
voltage, 1000 ms exposure time and 180 projections. 
A healthy B6CBAF1 mouse was used to find the 
optimal time point for a PET scan after 68Ga-Sienna+ 
injection (20 µL, 2.2 ± 0.9 MBq, 79 µg Fe) 
subcutaneously into left front paw. A scan was 
acquired for 2.5 h on a nanoScan PET-CT preclinical 
scanner (Mediso) 20 min after injection. CT was 
obtained with a 45 KVp tube voltage, 600 ms exposure 
time and 180 projections.  
For the tumour/SLN metastasis study NSG mice 
were imaged by PET-CT on day 21/22 after 
inoculations. 68Ga-Sienna+ (20 µL, 2.2 ± 0.9 MBq, 79 µg 
Fe) was injected subcutaneously into both left and 
right front paws. After 1 h, a 30 min scan was 
acquired. SPECT-CT images were reconstructed in a 
128 × 128 matrix using HiSPECT (Sci-vis GmbH, 
Germany) software package, and images fused using 
Bioscan InVivoScope (Bioscan, USA) software. 
PET-CT data were reconstructed using a Monte Carlo 
based full 3D iterative algorithm (Tera-Tomo, 
Mediso). Data were corrected for attenuation and 
scatter, and decay correction for the time of injection 
was applied. A total of 4 iterations and 6 subsets were 
applied. SPECT-CT Images were reconstructed with a 
voxel size of 0.16 x 0.16 x 0.16 mm and PET scans with 
a voxel size of 0.21 x 0.21 × 0.21 mm. Images were 
analysed using VivoQuant 2.50 software (Invicro 
LLC., USA) by drawing ROIs and calculating 
%ID/mL values. 
MR imaging 
MR imaging was performed 6 h after 
68Ga-Sienna+ injection using a 3T Philips Achieva MR 
scanner (Philips Healthcare, The Netherlands) 
equipped with a clinical gradient system (30 mTm-1, 
200 mT/m/ms) and a single-loop surface coil 
(diameter = 47 mm). Mice were anesthetised and 
placed on the coil in a prone position. After scout 
scans, a coronal 3D turbo spin echo T2-weighted scan 
(TR = 500 ms, TE = 61 ms, flip angle = 90°, FOV = 40 x 
30 x 12 mm3, acquired matrix 200 x 148, slice thickness 
= 0.5 mm, resolution = 0.2 x 0.2 mm, slice number = 
24, averages = 2, acceleration factor = 10, scan 
duration = 8 min 49.5 s) and a transverse 3D turbo 
spin echo T2-weighted scan were acquired (TR = 500 
ms, TE = 47 ms, flip angle = 90°, FOV = 31 x 31 x 8 
mm, acquired matrix 80 x 74, slice thickness = 0.5 mm, 
resolution = 0.4 x 0.4 mm, slice number = 16, averages 
= 4, acceleration factor = 10, scan duration = 6 min 1.5 
s). Finally, coronal 3D T2 maps were acquired with a 
turbo spin echo sequence (TR = 500 ms, TE = 21 ms, 
echo spacing = 28 ms, 5 echoes, flip angle = 90°, FOV = 
25 x 25 x 12 mm, acquired matrix 124 x 124, slice 
thickness = 0.5 mm, resolution = 0.2 x 0.2 mm, slice 
number = 24, averages = 1, acceleration factor = 10, 
scan duration = 18 min 32.5 s) and coronal 3D T2* 
maps with a turbo gradient echo sequence (TR = 44 
ms, TE = 4.7 ms, echo spacing = 5.0 ms, 8 echoes, flip 
angle = 25°, FOV = 25 x 25 x 12 mm, acquired matrix 
124 x 124, slice thickness = 0.5 mm, resolution = 0.2 x 
0.2 mm, slice number = 24, averages = 4, acceleration 
factor = 1, scan duration = 19 min 57.5 s). 
MR scans were analysed using OsiriX Lite 
software (Pixmeo SARL, Switzerland) and ROIs were 
drawn manually around the axillary LNs on the T2 
and T2* images. The ROI was drawn on the first 
image and then propagated to the rest of the echoes. 
Signal intensities of 3 consecutive slices containing the 
LNs were averaged and plotted against echo times. 
Exponential decay was fitted in GraphPad Prism 7 
(USA) using a one-phase decay. Spin-spin relaxation 
time T2 (ms) was calculated as 1/-K, K being the rate 
constant, and relaxation rate R2 (s-1) as 1/T2x1000. T2* 
and R2* were calculated the same way. 
Histology 
Mice were terminated after MR scans and 
fluorescence photographs were taken using a Nikon 
D5200 camera (Japan) and a Nikon DX AF-S NIKKOR 
18-55nn 1:3.5-5.6G ED II lens connected to an 
appropriate emission filter (SFA-LFS-RB, Nightsea, 
USA) using filter goggles and a fluorescent torch 
(emission 500 nm). Axillary LNs (metastatic and 
non-metastatic) were collected for histological 
analysis. LNs were fixed in 10% neutral buffered 




formalin (Pioneer Research Chemicals Ltd., UK) for a 
minimum of 2 days. LNs were processed into paraffin 
blocks using the Leica Biosystems tissue processor 
(Germany). Tissues were dehydrated through 70% 
EtOH 1.5 h, 100 % EtOH 5 h, xylene 3 h and paraffin 
wax 3 h. Nodes were cut into 5 µm sections and 
mounted on superfrost plus slides (VWR, USA). 
Immunohistochemistry staining was performed in the 
Ventana Discovery XT instrument (Ventana Medical 
Systems, USA), using the Ventana DAB Map 
detection Kit. Cancer cells were detected by GFP 
staining. Sections were pre-treated with EDTA buffer 
(45 min, Ventana cell condition 1 solution) before 
incubation in a primary antibody solution (1:5000 
ab290 8 h, Abcam, UK) and secondary swine 
anti-rabbit antibody (1:200 E0353 32 min, Dako, USA). 
Macrophages were stained with Iba1 antibody (1:250, 
4 h, Wako Chemicals GmbH, Germany) in the same 
way as in GFP staining, except that slides were 
incubated in the secondary antibody solution for 1 h. 
All slides were haematoxylin counterstained 
according to automatic protocol. Iron staining was 
performed with Perls Prussian blue protocol: sections 
were brought to distilled water and flooded with 
equal parts mixture of 2% ferrocyanide (VWR) and 2% 
hydrochloric acid (VWR) for 10 min. Slides were 
washed with water and counterstained with 0.1% 
neutral red stain (Acros Organics, Belgium) for 1 min. 
Slides were rinsed with water and dehydrated in 
absolute alcohol. Slides were digitised using the Leica 
SCN400F scanner with 40x magnification. 
Statistical analysis 
Statistical significances (P < 0.05) in the cell 
uptake studies were calculated by one-way ANOVA 
with Bonferroni correction and otherwise by 
two-tailed independent samples Student’s t-test using 
IBM SPSS Statistics 24 software (USA). 
Results 
68Ga-radiolabelling of Sienna+ 
Sienna+ was radiolabelled with 68Ga without 
using a chelator (Figure 1a). The reaction was 
optimised by testing the effect of pH (4, 5 and 6, 
before adding Sienna+) and temperature (40, 80 and 
100 °C) using a 10 min reaction time (Figure 1c). 
Analysis of the reaction conversion was performed by 
radio-TLC. The majority (>95%) of free 68Ga eluted 
with the solvent front, whereas 68Ga-Sienna+ stayed at 
the origin (Figure 1b). Increasing temperature and pH 
increased radiolabelling conversion (Figure 1c). 
Highest conversion of 68Ga-Sienna+ was obtained at 
100 °C at pH 6 in 10 min reaction time (Figure 1d). 
DLS measurements, however, showed aggregation at 
these conditions (data not shown, hydrodynamic size 
>100 nm). Therefore, for the in vitro/vivo experiments, 
Sienna+ was radiolabelled at pH 5 and 100 °C in 10 
min yielding 68Ga-Sienna+ with 93 ± 0.8 % 
radiochemical purity (RCP) and in 78 ± 1.4 % 
radiochemical yield (RCY) (low RCY due to loss of 
material during the sterile filtration step). The 
maximum specific activity (As ) obtained was 67 
MBq/mg of Fe (non-optimised and non-decay 
corrected). Hydrodynamic size was slightly higher 
and zeta potential lower than for unlabelled Sienna+ 
(Table 1). However, when the entire contents of the 
vial were labelled (using GMP-radiolabelling 
protocols), RCP and RCY >93% were obtained and no 
changes in hydrodynamic size/zeta potential were 
observed (Figure 1e, Table 1).  
Table 1. Hydrodynamic size (HDS) and zeta potential 
measurements (mean ± SD) (n = 3) 






Sienna+ 59 ± 0.7 74 ± 32 -18 ± 3.4 
68Ga-Sienna+ (GMP protocol) 57 ± 0.4 71 ± 32 -17 ± 1.2 
68Ga-Sienna+ (small scale) 71 ± 0.6 94 ± 48 -11 ± 2.1  
 
In vitro serum stability and cell uptake studies 
68Ga-Sienna+ in human serum at 37 °C showed 
good radiolabelling stability for at least up to 4 h (84 ± 
6 %, Figure 2a). The cell uptake study of 68Ga-Sienna+ 
was performed in the same breast cancer cell line as 
used in the in vivo study (3E.Δ.NT) and with two 
different macrophage cell lines (J774A.1 and 
RAW264.7.GFP). In all the cell lines tested, 
68Ga-Sienna+ uptake increased over time (Figure 2b). 
Both macrophage cell lines had significantly higher 
uptake than cancer cells at all time points (P < 0.001). 
Highest uptake (12 ± 1%) was found in J774A.1 cells at 
3 h, compared to 2.0 ± 0.1% in cancer cells. 
In vivo imaging and histology 
Six NSG mice were inoculated with 1×106 
3E.Δ.NT breast cancer cells into the left mammary fat 
pad. After 3 weeks, the primary tumour metastasised 
into the left axillary lymph nodes (LALNs), as 
assessed by 99mTcO4− SPECT (Figures 3a–b). 99mTcO4− 
is a substrate for hNIS, which is expressed by the 
cancer cells [30]. Using this method, metastasis in all 
LALNs could be confirmed. Metastasis was also 
observed in the lungs (Figure 3b). Organs that 
endogenously express NIS were also visible (stomach, 
salivary glands, thyroid and mammary glands) 
(Figures 3a–b). 3E.Δ.NT cells also express green 
fluorescent protein (GFP), allowing visual 
identification and confirmation of LALN metastasis 
by fluorescence detection during dissection (Figure 3f) 
and by GFP staining during histological analysis (vide 
infra). In one mouse metastasis was also found in the 




right axillary lymph node (RALN). In another mouse 
the health status of the RALN could not be confirmed 
and was excluded from the analysis. Therefore, in the 
final analysis, seven metastatic and four healthy LNs 
were included. 
Prior kinetic studies in tumour-bearing mice 
demonstrated slow SPIO draining (ca. 24h) into the 
axillary SLN when peri/intratumoural injections 
were used, which would prevent imaging using 68Ga. 
In clinical studies, Sienna+ has shown fast SLN 
accumulation (<1h); for this reason we evaluated paw 
injections, a well-proven route of administration of 
nanoparticulates that results in fast axillary LN 
accumulation. 68Ga-Sienna+ SLN uptake kinetics via 
paw injection were first assessed in a B6CBAF1 
mouse. There was a fast uptake in axillary LN within 
20-50 mins that did not considerably change for up to 
170 min (data not shown). Therefore, in the 
3E.Δ.NT/NSG model, PET scans were performed 1 h 
after injection of 68Ga-Sienna+ into both front paws. 
MRI was performed 6 h post injection due to the 
logistics of these experiments. PET imaging showed 
accumulation of 68Ga-Sienna+ in healthy axillary LNs 
(SLNhealth), as well as - although at a significantly 
lower uptake level - healthy brachial LNs (Figure 3c 
and 3e). The high uptake in SLNhealth allows for 
differentiation from SLNmet, which had only 
background uptake (Figure 3c). Image-based 
quantification demonstrated a significantly higher 
uptake in axillary SLNhealth compared to SLNmet (2.2 ± 
 
 
Figure 1. Radiolabelling studies: (a) 68Ga-radiolabelling of Sienna+, (b) Radio-TLC of unchelated 68Ga and 68Ga-Sienna+; (c) Radiolabelling yield optimization at different pH and 
temperatures (mean ± SEM, n = 3–4); (d) Radiolabelling yields at 100 °C pH 6 using different reaction times (mean ± SEM, n = 3); (e) DLS measurement comparison of Sienna+ 
and 68Ga-Sienna+ (GMP protocol). 
 
Figure 2. In vitro experiments: (a) Stability of 68Ga-Sienna+ in human serum at 37 °C (mean ± SEM, n = 3). (b) Cell uptake of 68Ga-Sienna+ in breast cancer cells (3E.Δ.NT) and 
macrophages (J774A.1 and RAW264.7.GFP) at different time points (mean ± SEM, n = 3).  




0.9 vs. 1.1 ± 0.2 %ID/mL, P = 0.006; Figure 3g). It 
should be noted that the %ID/mL values for SLNhealth 
are likely to be an underestimation of the real value. 
This is due to their small size that prevented accurate 
segmentation by CT and the substantial partial 
volume effect from the PET signal that was used for 
measuring their volume. 68Ga-Sienna+ was also found 
in the liver (5.3 ± 1.2 %ID/mL), heart (2.1 ± 0.3 
%ID/mL), lungs (1.2 ± 0.3 %ID/mL) and bladder (1.5 
± 0.4 %ID/mL) (Figure 3e). In other organs, uptake 
was below 1 %ID/mL. Most of the injected 
68Ga-Sienna+ remained in the injection site at the time 
of the PET scan (67 ± 14 %ID/mL). Ex vivo 
biodistribution studies were not possible due to the 
timing of the imaging experiments (MRI was 
performed 6 h after PET imaging), which resulted in 
decay of the radionuclide. 
MRI identified metastasis in SLNs that could not 
be identified by preclinical PET (Figure 4). SLNmet 
were identifiable in MRI due to their large size and 
high signal intensity in T2-weighted images due to the 
absence of 68Ga-Sienna+ (Figures 3d and 4). 
Quantification of the MR images demonstrated these 
differences with SLNhealth having significantly lower 
(T2*)/higher (R2*) values than SLNmet (Figure 3h). T2 
and R2 were not significantly different between 
SLNhealth and SLNmet, as expected due to the higher 
sensitivity of T2*-weighted sequences for iron contrast 
compared to T2-weighted MRI [31].  
SLNs from the imaging study with different 
levels of metastasis and therefore macrophage density 
were analysed by histology using GFP staining 
(3E.Δ.NT cells), Iba1 (macrophages) and Perl’s 
Prussian blue (iron/Sienna+) (Figure 4). The location 
 
 
Figure 3. In vivo imaging in the 3E.Δ.NT metastatic breast cancer model: (a) whole-body MIP SPECT-CT showing uptake of 99mTcO4- in the primary tumour and left axillary lymph 
node (SLNmet, filled arrowhead) due to metastasis, as well as uptake in NIS-expressing organs (thyroid/salivary glands and stomach); (b) coronal (top) and transversal (bottom) 
SPECT-CT images for the same mouse centered in SLNmet and showing presence of lung metastases; (c) coronal and transversal PET-CT images for the same mouse showing 
uptake of 68Ga-Sienna+ in SLNhealth (open arrowhead), but not in SLNmet. Note that, for clarity, the injection site and corresponding PET signal is not shown; (d) coronal and 
transversal MRI images (T2-weighted 3D turbo spin echo) of the same mouse showing the uptake of 68Ga-Sienna+ in SLNhealth, but not in SLNmet that appear bright and enlarged; 
(e) MIP PET-CT image showing the relative uptake of 68Ga-Sienna+ in brachial and axillary SLNhealth. Note that, for clarity, the injection site and corresponding PET signal is not 
shown; (f) Fluorescence photograph of same animal as in A–E showing the presence of metastasis in SLNmet but not in the contralateral area where SLNhealth is located. All images 
are in right-left orientation; (g,h) 68Ga-Sienna+ uptake quantification (mean ± SEM) in SLNmet and SLNhealth by (g) PET and (h) MRI. 




and density of the GFP stain was inversely correlated 
with that of the macrophage/iron stain and the 
macrophage-rich areas directly correlated to the iron 
stain. SLNmet were positive for GFP stain whereas 
healthy SLNs were negative (It should be noted here 
that there was weak non-specific binding of the GFP 
stain to SLNhealth, despite absence of GFP-expressing 
3E.Δ.NT cancer cells as confirmed by lack of 
fluorescence). One metastatic SLNmet showed a 
concentrated localization of macrophages and 
Sienna+ whereas fully metastatic SLNmet presented a 
disperse distribution and low density of macrophages 
and absence of Sienna+. SLNhealth showed a high 
density and co-localization of both macrophages and 
Sienna+.  
Discussion  
The aim of this study was to synthesise and 
evaluate the potential of 68Ga-Sienna+ for locating and 
characterizing the health status of SLNs with 
PET-MRI. Sienna+ is a clinically approved SPIO and 
CE-marked device used in several clinical trials in 
conjunction with a magnetometer for intrasurgical 
SLN guidance [32]. 68Ga was chosen due to its 
availability from a GMP-grade generator, its short 
half-life ideal for SLN imaging, and the possibility of 
using a chelate-free approach that allows for simple 
GMP compatible radiolabelling [33–35]. Sienna+ 
nanoparticles were labelled with 68Ga without a 
chelator in a fast and efficient way. A temperature of 
≥80 °C was found to be required for efficient labelling. 
Lower temperatures (40 °C) resulted in RCY below 
55%, independently of pH. At high temperatures 
(100°C) and pH ≥ 6 aggregation occurred. This was 
prevented by performing the reaction at pH 5. For 
animal experiments the nanoparticle solution had to 
be concentrated due to the small volume required for 
injection (20 µL). This caused a slight increase in the 
average hydrodynamic particle size, most likely due 
to minor aggregation as a result of the higher 
concentration (Table 1). This slight size increase is not 
expected to result in any significant changes to the 
pharmacokinetics/biodistribution of Sienna+. 
Furthermore, when the entire contents of the vial of 
Sienna+ (2 mL) were radiolabelled (GMP-protocol) 
the physicochemical properties of the nanoparticle 
(hydrodynamic size and zeta potential) remained 
unchanged (Table 1). The highest specific activity 
achieved in our studies (As = 67 MBq/mg of Fe) 
would theoretically allow preparation of up to 4 GBq 
of 68Ga per vial (each vial contains ca. 60 mg Fe).  
 The RCP achieved was within the limits of the 
European Pharmacopoeia for 68Ga radiotracers such 
as [68Ga]Ga-DOTATOC (≥91% RCP) [36], making 
purification from free 68Ga unnecessary. It is not 
known where exactly 68Ga binds to Sienna+, to the 
 
Figure 4. Histological analysis and PET-MRI coronal images of corresponding lymph nodes. Comparison of histology for fully metastatic (top row - with low macrophage 
density), metastatic (mid-row - medium macrophage density) and healthy lymph nodes (bottom row - high macrophage density) and corresponding MRI and PET-CT images 
where SLNs are marked with an arrow (SLNmet: filled arrowhead; SLNhealth: open arrowhead). PET signal from the injection site is marked with an asterisk. Cancer cells (GFP 
stain) and macrophages (Iba1 stain) stain dark brown, iron (Pearls stain) in blue. Note weak non-specific GFP staining in SLNhealth to non-cancer cells. Scale bars represent 100 µm. 
 




coating or the magnetite core. Previous reports using 
this radiolabelling method, however, suggest 
radiometal binding to the magnetite core [33]. 
68Ga-Sienna+ was sufficiently stable in serum, with 84 
± 6 % of 68Ga-Sienna+ intact after 4h incubation. It 
should be noted that when used in vivo, Sienna+ is 
injected subcutaneously, and not intravenously. 
Furthermore, human studies with Sienna+ report fast 
lymph node uptake, as early as 20 min post injection 
[37]. 
 As expected from the avidity of dextran-coated 
SPIOs for macrophages, the in vitro cell uptake studies 
were in agreement with the in vivo PET-MRI study, 
showing a significantly higher uptake of 68Ga-Sienna+ 
in macrophages/SLNhealth compared to cancer 
cells/SLNmet (Figures 2–3) [38]. These findings were 
confirmed by histology. PET allowed sensitive 
detection of healthy SLNs (Figure 3e). MRI, on the 
other hand, allowed the identification of their health 
status (Figure 3d). Having the complementary 
information from both PET and MRI and using a 
bimodal agent allows highly sensitive localization and 
characterization of SLN and their status at the 
whole-body level. It is important to mention that, in 
our preclinical study, partial metastasis could only be 
detected by MRI by low signal intensity areas (healthy 
LN tissue) within high signal intensity SLNs 
(metastatic LN tissue) (Figure 4) whereas by PET 
these SLNs did not show any measurable signal due 
to the highly localised [68Ga]Ga-Sienna+/macrophage 
density that is below the spatial resolution limits of 
preclinical PET due to the partial volume effect. The 
larger size of human lymph nodes should allow the 
detection of partial metastasis by both PET and MRI. 
A likely drawback for the clinical use of 68Ga-Sienna+ 
PET-MRI is that fully metastatic lymph nodes, which 
do not take up radiolabelled SPIOs, may remain 
undetected. This could potentially be overcome by the 
inclusion of diffusion weighted (DW)-MRI into the 
protocol, which does not depend, but can benefit, 
from SPIO contrast [39,40].  
 Looking into how 68Ga-Sienna+ could be used 
for clinical LN imaging, we envisage that after 
subcutaneous injection of 68Ga-Sienna+, in the same 
way as 99mTc colloids and Sienna+ are currently used 
for SLNB, patients could undergo a PET-MRI 
examination where PET will be used first to identify 
the location of SLNhealth and partially-metastatic 
SLNmet, and second to guide high resolution MRI to 
these areas for characterization of their health status. 
This MR step could include DW-MRI in addition to 
T2/T2*-weighted sequences to identify fully 
metastatic SLNmet. One challenge to overcome in 
order to provide confidence to the use of preoperative 
SPIO-MRI as a substitute for ex vivo histology will be 
to prevent false positives and negatives. Studies to 
date using SPIO-MRI in patients have shown a very 
low number of false-positives (and mostly due to the 
presence of fatty hilum)[41]. Hence it seems that a 
more challenging problem will be to prevent false 
negatives, particularly those involving 
micrometastases. Indeed, human studies thus far have 
allowed the detection of LN micrometastases of ca. 
2mm, and a non-optimal number of false-negatives 
(e.g. 40% of false negatives later identified as 
micrometastases by histology [41]). Several challenges 
should be overcome to improve this. First, current 
clinical SPIO/MRI technology does not allow the 
detection of smaller lesions due to its inherent spatial 
resolution limitations (potentially sub-millimetre, but 
restricted by scan time limitations, patient movement 
and other factors). The second challenge is that the 
presence of SPIO-related signal in the healthy portion 
of LNs may obscure small metastatic lesions. To 
improve this, complementary imaging tests using 
higher spatial resolution techniques such as 
photoacoustic imaging [9], and/or improvements in 
MRI technology (high-resolution 7T magnets, 
improved coils/sequences for SLN SPIO imaging) or 
SPIO design (improved relaxation properties and 
doses), may be able to address these limitations in the 
future. After imaging, 68Ga-Sienna+ could then be 
detected visually during surgery (or using the 
standard gamma-probes if 68Ga is still detectable) or 
with the help of a handheld magnetometer, even days 
after injection [42]. 
Conclusion 
 With the aim of developing a preoperative 
PET-MRI method to inform sentinel lymph node 
biopsies (SLNB), we have radiolabelled a 
clinically-approved SPIO for sentinel lymph node 
localization (Sienna+) with 68Ga using a 
GMP-compatible, chelate-free method. In vitro and in 
vivo studies were performed to confirm the ability of 
68Ga-Sienna+ in combination with PET-MRI, to locate 
and characterise SLNs using a breast cancer mouse 
model that develops spontaneous lymph node 
metastases. 68Ga-Sienna+ uptake levels in SLNs, as 
measured by PET-MRI followed by histological 
confirmation, correlate with the level of 
metastasis/macrophage density. Thus, we have 
provided proof of concept that 68Ga-Sienna+ PET-MRI 
could be a useful preoperative imaging tool for 
informing SLNB procedures by allowing the 
localization at the whole body level (using PET) and 
characterization (using PET and MRI) of local and 
distant SLNs from a single imaging session. This 
would be particularly useful in cancers where the 
location of the primary tumour, and hence lymphatic 




drainage, is variable (e.g. melanoma). One particular 
challenge for clinical translation will be the avoidance 
of false negatives/positives, and it is expected that 
improvements in MRI/SPIO technology may be able 
to address this. In future clinical studies, bigger 
sample sizes and blinded evaluation would be 
required to confirm the absence of false 
negatives/positives and to determine cut-off values 
for image-based quantification and intralymphatic 
SPIO distribution that would allow accurate 
prediction of SLN health status in patients.  
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